|
Neonatal Intensive Care Drug Manual
|
| bet | 604/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
| Valgancyclovir
|
Revision Date : 24-9-2019
|
Approved: TC, KOH
|
Alert
|
Oral valganciclovir is a cytotoxic agent.
|
Indication
|
1) Treatment of severe or moderately severe, symptomatic congenital CMV, or
2) Treatment of acute severe CMV disease.
|
Action
|
Valganciclovir is an L-valyl ester salt (prodrug) of ganciclovir which, after oral administration, is rapidly converted to ganciclovir by intestinal and hepatic esterases. Synthetic nucleoside analogue of 2-deoxyguanosine that inhibits replication of herpes viruses. Sensitive human viruses include cytomegalovirus, herpes simplex virus 1 and 2, herpes virus type 6, 7 and 8, Epstein-Barr virus, varicella zoster virus and hepatitis B virus.
|
Drug Type
|
Antiviral.
|
Trade Name
|
Valcyte
|
Presentation
|
Valganciclovir hydrochloride powder for oral solution. The reconstituted solution contains 50 mg/mL valganciclovir and appears clear, colourless to brownish-yellow in colour.
|
Dosage/Interval
|
16 mg/kg/dose 12 hourly*
*In acute, severe CMV disease including hepatitis, use IV ganciclovir as initial therapy and change over to oral valganciclovir once clinically stable.
Duration of treatment:
Treatment of severe or moderately severe, symptomatic congenital CMV – maximum 6 months.
Treatment of acute severe CMV disease – as per the disease progress and response.
|
Route
|
Oral
|
Preparation/Dilution
|
|
| |
